Evidence map›Paper›PMID 32555294›Full record

ArticleScientific reports2020

An integrated Asian human SNV and indel benchmark established using multiple sequencing methods.

Chuanfeng Huang, Libin Shao, Shoufang Qu, Junhua Rao, Tao Cheng, Zhisheng Cao, Sanyang Liu, Jie Hu, Xinming Liang, Ling Shang and 11 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Chuanfeng Huang *National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing, 10050, P. R. China.
Libin Shao *BGI-Qingdao, BGI-Shenzhen, Qingdao, Shandong, 266555, P. R. China.ORCID http://orcid.org/0000-0002-1789-6005
Shoufang Qu *National Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing, 10050, P. R. China.
Junhua Rao *MGI, BGI-Shenzhen, Shenzhen, Guangdong, 518083, P. R. China.ORCID http://orcid.org/0000-0002-9568-4278
Tao ChengBerryGenomics Co., Ltd. Building #5, 4 Science Park Road, ZGC Life Science Park, Beijing, 102200, P. R. China.
Zhisheng CaoTianjin Novogene Bioinformatic Technology Co., Ltd. Entrepreneurial Headquarters Base B07-B09, Wuqing Development Zone, Tianjin, 301700, P. R. China.
Sanyang LiuAnnoroad Gene Technology, Building B1, Yard 88, kechuang 6Rd, Beijing Economic-Technological Development Area, Beijing, 102200, P. R. China.
Jie HuBGI-Qingdao, BGI-Shenzhen, Qingdao, Shandong, 266555, P. R. China.
Xinming LiangMGI, BGI-Shenzhen, Shenzhen, Guangdong, 518083, P. R. China.
Ling ShangBerryGenomics Co., Ltd. Building #5, 4 Science Park Road, ZGC Life Science Park, Beijing, 102200, P. R. China.
Yangyi ChenCapitalBio Genomics Co., Ltd., Building 11, GuanTai Biotechnology Cooperation Incubation Center, No.1, Taoyuan Road, Songshan Lake Hi-Tech Industrial Development Zone, Dongguan, Guangdong, 523808, P. R. China.
Zhikun LiangGuangzhou Daruia Biotechnology Co. Ltd., 5 buildings No. 11 Nanxiang Third Road, Science City, Luogang District, Guangzhou, Guangdong, 510663, P. R. China.
Jiezhong ZhangAnnoroad Gene Technology, Building B1, Yard 88, kechuang 6Rd, Beijing Economic-Technological Development Area, Beijing, 102200, P. R. China.
Peipei ChenTianjin Novogene Bioinformatic Technology Co., Ltd. Entrepreneurial Headquarters Base B07-B09, Wuqing Development Zone, Tianjin, 301700, P. R. China.
Donghong LuoCapitalBio Genomics Co., Ltd., Building 11, GuanTai Biotechnology Cooperation Incubation Center, No.1, Taoyuan Road, Songshan Lake Hi-Tech Industrial Development Zone, Dongguan, Guangdong, 523808, P. R. China.
Anna ZhuGuangzhou Daruia Biotechnology Co. Ltd., 5 buildings No. 11 Nanxiang Third Road, Science City, Luogang District, Guangzhou, Guangdong, 510663, P. R. China.
Ting YuNational Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing, 10050, P. R. China.
Wenxin ZhangNational Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing, 10050, P. R. China.
Guangyi FanBGI-Qingdao, BGI-Shenzhen, Qingdao, Shandong, 266555, P. R. China.
Fang ChenMGI, BGI-Shenzhen, Shenzhen, Guangdong, 518083, P. R. China. fangchen@genomics.cn.
Jie HuangNational Institutes for food and drug Control (NIFDC), No.2, Tiantan Xili Dongcheng District, Beijing, 10050, P. R. China. jhuang5522@126.com.
National Institutes for Food and Drug Control · CNBGI Group (China) · CNAnnoroad Gene Technology (China) · CNBerry Oncology (China) · CNGuangzhou Building Materials Institute · CNNovogene Bioinformatics Institute · CNQingdao Center of Resource Chemistry and New Materials · CNSongshan Lake Materials Laboratory · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sequencing technologies have been rapidly developed recently, leading to the breakthrough of sequencing-based clinical diagnosis, but accurate and complete genome variation benchmark would be required for further assessment of precision medicine applications. Despite the human cell line of NA12878 has been successfully developed to be a variation benchmark, population-specific variation benchmark is still lacking. Here, we established an Asian human variation benchmark by constructing and sequencing a stabilized cell line of a Chinese Han volunteer. By using seven different sequencing strategies, we obtained ~3.88 Tb clean data from different laboratories, hoping to reach the point of high sequencing depth and accurate variation detection. Through the combination of variations identified from different sequencing strategies and different analysis pipelines, we identified 3.35 million SNVs and 348.65 thousand indels, which were well supported by our sequencing data and passed our strict quality control, thus should be high confidence variation benchmark. Besides, we also detected 5,913 high-quality SNVs which had 969 sites were novel and  located in the high homologous regions supported by long-range information in both the co-barcoding single tube Long Fragment Read (stLFR) data and PacBio HiFi CCS data. Furthermore, by using the long reads data (stLFR and HiFi CCS), we were able to phase more than 99% heterozygous SNVs, which helps to improve the benchmark to be haplotype level. Our study provided comprehensive sequencing data as well as the integrated variation benchmark of an Asian derived cell line, which would be valuable for future sequencing-based clinical development.

Indexed as

AdultAsian PeopleBenchmarkingGenome, HumanHaplotypesHigh-Throughput Nucleotide SequencingHumansINDEL MutationMalePolymorphism, Single NucleotideReference Standards

Identifiers

PMID32555294
PMCPMC7300012
OpenAlexW3035979873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.